web analytics
4.6 C
Munich
Sunday, April 18, 2021

Covi-Shield; the Rise of Sorrento Therapeutics Inc (NASDAQ: SRNE)

Sorrento Therapeutics Inc (NASDAQ: SRNE) is making a strong move up the charts in recent trading as coronavirus stocks heat up across the board. As New coronavirus cases have been spiking in the US and globally proving the virus is here to stay and won’t be disappearing anytime soon. At the same time results and data coming back from the Pfizer vaccine and Lilly Mab are looking less and less promising the more we learn. Sorrento Therapeutics “COVI-SHIELD” is a highly effective combination of antibodies designed to both block different strains of coronavirus and already has FDA approval for clinical trials.

Sorrento Management recently stated that “each dose of COVI-SHIELD will deliver a cocktail of three neutralizing antibodies that together would recognize three unique regions of the SARS-CoV-2 Spike protein to ward off the disease.”

Sorrento Therapeutics Inc (NASDAQ: SRNE) together with its subsidiaries is a clinical stage and commercial biopharma company focused on delivering innovative and clinically meaningful therapies to patients and their families to address unmet medical needs. The Company also has programs assessing the use of its technologies and products in autoimmune, inflammatory and neurodegenerative diseases. At its core, Sorrento Therapeutics is an antibody-centric company leveraging its proprietary G-MAB™ library and targeted delivery modalities to generate the next generation of therapeutics. The Company’s fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, CTLA-4, c-MET, VEGFR2, CCR2 and CD137 among others.

Sorrento and Mount Sinai Health System in New York City joined forces to develop an antibody cocktail to shield against Covid-19 infection for up to two months. The treatment, called COVI-SHIELD, is designed to be administered as often as necessary, with each dose expected to provide antiviral protection for health care and other essential workers. “COVI-SHIELD.” is a highly effective combination of antibodies designed to both block different strains of coronavirus, as well as prevent a known vaccine and antibody complication that can actually make viral infections much worse. COVI-SHIELD has FDA approval for clinical trials. Sorrento Therapeutics says that each dose of COVI-SHIELD will deliver a cocktail of three neutralizing antibodies that together would recognize three unique regions of the SARS-CoV-2 Spike protein to ward off the disease.

Sorrento’s coronavirus programs are:

  • COVI-TRACE™ (Diagnostic Test for the Detection of SARS-CoV-2 in Saliva)
  • COVI-TRACK™ (Antibody Test for the Detection of Antibodies to SARS-CoV-2 in blood)
  • COVI-GUARD™ (Neutralizing Antibody – STI 1499)
  • COVI-AMG™ (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020)
  • COVI-DROPS™ (Intranasal COVI-AMG Neutralizing Antibody – STI 2099)
  • COVI-SHIELD™ (Neutralizing Antibody Cocktail)
  • COVIDTRAP™ (ACE2 Receptor Decoy – STI 4398)ABIVERTINIB (Cytokine Storm – STI 5656)
  • SALICYN-30 (Anti-viral – STI 2030)
  • MESENCHYMAL STEM CELL (Acute Respiratory Distress Syndrome – STI 8282)

To Find out the inside Scoop on SRNE Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

SRNE

Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir®”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD™, COVI-AMG™, COVI-SHIELD™ and COVI-DROPS™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.

Sorrento’s commitment to life-enhancing therapies for patients is also demonstrated by the Company’s effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients.  SEMDEXA is in a pivotal phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.

On November 11 SRNE announced it is filing an investigational new drug application (IND) for intranasal (IN) COVI-DROPS (STI-2099) to study the safety and pharmacokinetics in both healthy volunteers and patients with mild COVID-19. As Sorrento previously announced, in preclinical studies, high potency STI-2099 demonstrated a 100% neutralizing effect (both in vitro and in vivo) and at a very low dose prevented SARS-CoV-2 from infecting healthy cells and causing COVID-19-like disease in Syrian golden hamsters. A single intra-nasal administration of STI-2099 12 hours after infection prevented disease-associated weight loss in treated hamsters. The impact of the treatment was observed within 24 hours of STI-2099 treatment, demonstrating unique disease treatment properties as compared to intravenously administered antibodies.

Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics stated: “We believe STI-2099 has the potential to be broadly deployable for early treatment in an outpatient setting. The intranasal route is expected to be enabled by the high potency of the antibody and is quite promising against this highly contagious respiratory pathogen. In addition, it is now understood that COVID-19 is a local and systemic disease; therefore, we believe the best course of action would be to attack this highly contagious pathogenic virus both locally and systemically.”

For more on Covi-Shield Subscribe Right Now!

SRNE is making a strong move up the charts in recent trading as coronavirus stocks heat up across the board. As New coronavirus cases have been spiking in the US and globally proving the virus is here to stay and won’t be disappearing anytime soon. At the same time results and data coming back from the Pfizer vaccine and Lilly Mab are looking less and less promising the more we learn. Sorrento Therapeutics “COVI-SHIELD” is a highly effective combination of antibodies designed to both block different strains of coronavirus and already has FDA approval for clinical trials. Sorrento and Mount Sinai Health System in New York City joined forces to develop an antibody cocktail to shield against Covid-19 infection for up to two months. The treatment, called COVI-SHIELD, is designed to be administered as often as necessary, with each dose expected to provide antiviral protection for health care and other essential workers. “COVI-SHIELD.” is a highly effective combination of antibodies designed to both block different strains of coronavirus, as well as prevent a known vaccine and antibody complication that can actually make viral infections much worse. COVI-SHIELD has FDA approval for clinical trials. Sorrento Therapeutics says that each dose of COVI-SHIELD will deliver a cocktail of three neutralizing antibodies that together would recognize three unique regions of the SARS-CoV-2 Spike protein to ward off the disease. We will be updating on SRNE when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SRNE.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in SRNE either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.